Avanos Medical to Be Acquired, Taken Private

An update from Avanos Medical ( (AVNS) ) is now available.

On April 13, 2026, Avanos Medical agreed to be acquired by affiliates of American Industrial Partners in an all-cash merger valuing the company at about $1.272 billion, with shareholders to receive $25.00 per share, a premium of more than 70% to the prior day’s close. The board unanimously approved the deal, which is expected to close in the second half of 2026, remains subject to shareholder and regulatory approvals, and will see Avanos taken private and delisted from the NYSE while employee equity awards are cashed out under agreed terms.

The merger agreement includes customary closing conditions, a no‑solicitation covenant with a fiduciary out for superior proposals, and a $37.5 million termination fee payable under certain scenarios if Avanos walks away for a better offer. For American Industrial Partners, which specializes in operational turnarounds, the transaction provides a platform in differentiated medical devices, while Avanos’ leadership says the deal should enhance resources, support its innovation roadmap and strengthen its competitive position for patients, customers and employees.

The most recent analyst rating on (AVNS) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.

Spark’s Take on AVNS Stock

According to Spark, TipRanks’ AI Analyst, AVNS is a Neutral.

The score is held back mainly by weak and inconsistent profitability plus a recent free-cash-flow downshift, partially offset by a conservative balance sheet and improving revenue. Technical signals are currently bearish-to-neutral, and valuation lacks support with a high P/E and no dividend. The latest earnings call adds some upside due to constructive 2026 guidance and mitigation plans, though tariffs create meaningful near-term margin risk.

To see Spark’s full report on AVNS stock, click here.

More about Avanos Medical

Avanos Medical, Inc. is a U.S.-based medical technology company that develops, manufactures and markets medical device solutions aimed at helping patients return to normal activities. Headquartered in Alpharetta, Georgia, it focuses on critical healthcare needs such as enteral nutrition from hospital to home and reducing opioid use in post-surgical pain management, holding leading positions in multiple product categories worldwide.

Average Trading Volume: 578,903

Technical Sentiment Signal: Sell

Current Market Cap: $659.5M

Learn more about AVNS stock on TipRanks’ Stock Analysis page.